ficant reduction in the rate of biopsy-proven acute rejection during the first 6 months after kidney trans-
Introduction
metabolized by a common pathway [11] . A recent paper showed higher MPA trough levels and increased Three large, double-blind, randomized trials have AUC 0-12 values in kidney recipients receiving shown that the addition of mycophenolate mofetil tacrolimus+MMF compared to patients receiving (MMF ) to an immunosuppressive regimen consisting CsA+MMF [12] . The authors suggested an inhibitory of cyclosporin (CsA) and prednisone results in a signieffect of tacrolimus on the conversion of MPA to MPAG to be the mechanism of interaction. However, Correspondence and offprint requests to: Dr P. J. H. Smak Gregoor, the data we present in this paper show in fact that the 
Subjects and methods
the non-CsA-treated patients (10 mg). None of the patients in either group used any drug known to
In a cross-sectional study we examined the effect of CsA on interact with MMF, nor was a pattern present with MPA trough levels. Included were 11 patients treated with any drug being more prominent in either group.
MMF and prednisone, 1 year post-transplant, the 'non-CsA group'. All 11 patients had been on MMF treatment for at
The median body weight and height of the CsA vs least 3 months and had stopped CsA treatment for at least the non-CsA-treated group was 78 kg (62-92) vs 82 kg 2 months.
(61-100) and 176 cm (159-193) vs 174 cm (153-185) From January 1997 all new kidney transplant recipients respectively. This was not a statistically significant are treated with a triple-drug regimen consisting of difference for weight (P=0.5, Mann-Whitney) or CsA+MMF+prednisone during the first 6 months after height (P=0.7, Mann-Whitney). The intraindividual transplantation. These patients form the 'CsA group'. All range for MPA trough levels per patient in the CsA vs MPA samples from the 18 patients in this group were also the non-CsA treated group is shown in Table 1. drawn after treatment with CsA and MMF for at least 3 months. The median time from transplantation was 5 months (3-10) in the CsA group.
Discussion
Fasted plasma MPA trough levels (EMIT-Mycophenolic Acid Assay, Behring Diagnositics Inc, San Jose, Ca, USA) were routinely measured from February 1997, always 12 h For tacrolimus and CsA most clinicians agree that after the previous dose. This immunoassay has been reported routine drug monitoring improves the safety and effito give good agreement with an HPLC assay [13] . For CsA cacy of these drugs in transplant recipients. Although whole-blood trough levels the EMIT immunoassay was also in kidney transplant recipients a clear reduction in the used. For both CsA and MPA we participate in the quality incidence of acute rejections with MMF has been using therapeutic drug monitoring still has to be shown. This holds true for MPA monitoring in relation to acute rejection as well as to side-effects.
Results
This paper shows the results of MPA monitoring in two groups of kidney transplant recipients. Although Figure 1 shows the clear difference in MPA trough all patients were being treated with a total daily dose levels between the two groups. In the CsA group MPA of 2 g MMF, a highly significant difference in MPA trough levels ranged from 0.49 to 4.98 mg/l (mean concentrations was found between the patients treated 1.98±0.12, median 2.02), whereas the range in the with CsA+MMF+prednisone and those treated with non-CsA group was from 1.02 to 9.30 mg/l (mean MMF+prednisone only. How CsA and MMF interact 4.38±0.40, median 3.75). The difference between the cannot be concluded from this study. Interaction at two groups is highly significant (two-sided P-value the level of absorption is unlikely, as bioavailability of <0.0001; Mann-Whitney test). The median serum MMF is reported to be almost 100% in healthy controls creatinine levels in the CsA-treated patients was as well as in transplant recipients. However, within the 118 mmol/l (range 61-246, mean 124) and not different from the non-CsA-treated patients (median 110, range 72-213, mean 118, P=0.72) . The average prednisone 
